We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Eurofins Technologies

Eurofins Technologies, part of the Eurofins Scientific group, is a fast-growing, global provider of diagnostic test k... read more Featured Products: More products

Download Mobile App





Eurofins Launches New Multiplex PCR Assay for Rapid Detection of B.1.617 Kappa SARS-CoV-2 Variant

By LabMedica International staff writers
Posted on 04 Jun 2021
Eurofins Technologies (Ebersberg, Germany) has launched its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617 (India), B.1.427/B.1.429 (California/USA), B.1.351 (South Africa) or P.1 (Brazil).

The assay facilitates the identification of the relevant mutations E484Q, E484K and L452R in one reaction combined with the simultaneous discrimination from the S gene E484 wildtype variant. More...
These mutations have been associated with reports of potential decreased efficacy of certain vaccines and an increase in the transmissibility of the virus.

GSD NovaType III SARS-CoV-2 is the latest addition to the GSD NovaType product line, a continuously updated panel of single and multiplex assays for the screening and detection of emerging Variants of Concern (VOC) and of Interest (VOI) on positive samples. These assays may play an important role in the fight against COVID-19 by enabling the rapid identification of new variants that may endanger the success of global vaccination campaigns and the implementation of enhanced isolation, testing and vaccination measures in affected areas. GSD NovaType III SARS-CoV-2 will be available as a research-use-only kit by the June 9. A CE marked version is expected by the second half of June.




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Acute lymphoblastic leukemia in children and young people requires careful relapse risk assessment as treatment expands beyond standard chemotherapy. (Image Credit: Shutterstock)

New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL

Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea

Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.